FTC secures order against Havas over ad-market collusion [marketing-compliance]
The FTC announced on June 30, 2026 that Havas Media Group USA agreed to a proposed order resolving allegations that it took part in unlawful collusion affecting where advertising dollars flowed (ftc.gov). The named conduct sits at the agency-holding-company level, far from a single clinic, but the throughline for marketers is that the FTC is actively policing coordination and steering in the ad ecosystem you buy into. If your growth runs through a managed-media shop or a shared agency arrangement, the question worth asking is how your spend gets allocated and whether anything in that arrangement steers on grounds other than your performance. Ask your agency to document how media decisions get made on your account, and keep your own record of what you paid for and what you got.
Source: ftc.gov (2026-06-30)

Minnesota's House File 2779 tightens MSO transparency, per DJ Holt Law [operator-intel]
DJ Holt Law published a July 1, 2026 read on Minnesota's House File 2779, which the firm describes as adding transparency requirements that force a closer look at legacy entity separations and contract execution in MSO structures (djholtlaw.com). This is a law firm's analysis of a state statute, secondary to the bill text itself, but the direction matches what operators are seeing state by state: the friendly-physician and management-services arrangements that passed without scrutiny a few years ago now draw transparency mandates that expose how the entities actually relate. A Minnesota hormone or peptide clinic running on an older MSO template is the profile at issue. Have counsel read HF 2779 against your current structure and confirm your entity separations and contracts hold up to the transparency the statute now demands.
Source: djholtlaw.com (2026-07-01)

FTC halts a subscription enterprise over hidden charges and hard-to-cancel billing [marketing-compliance]
At the FTC's request, a federal court temporarily halted the Genesis Tech enterprise, 15 corporations and eight individuals, over allegations of misleading internet subscription schemes with unauthorized billing and cancellation that was made difficult (June 17, 2026, ftc.gov). Peptide, HRT, and GLP-1 telehealth largely runs on recurring memberships, which puts this squarely in your lane: the FTC is treating hidden recurring charges and cancellation friction as the deception, and the negative-option rules apply whether you sell software or a monthly injectable membership. A signup flow that is easy to enter and hard to leave is now a documented enforcement target. Have counsel walk your own subscribe-and-cancel path end to end and confirm your disclosures, consent, and cancellation are as simple as your signup.
Source: ftc.gov (2026-06-17)

Riders on the Storm Part 2: the drug provisions [operator-intel]
Hyman, Phelps & McNamara published Part 2 of its "Riders on the Storm" series on June 25, 2026, narrowing from the general appropriations picture to the drug provisions specifically (thefdalawblog.com). This is analysis of report language, secondary and non-binding, but the drug section is where compounding, importation, and prescribing directives tend to hide, and this is the middle installment between the funding overview in Part 1 and the compounding and GLP-1 detail in Part 3. Reading the three in sequence is the point: the series maps congressional intent onto the FDA workstreams that touch this industry. Have counsel pull the drug-provisions section and note any directive that names compounding, GLP-1s, or telehealth so you are not surprised when it resurfaces as guidance.
Source: thefdalawblog.com (2026-06-25)

Cerilliant applies to import controlled substances [compounding-bulks]
DEA published a notice on June 15, 2026 that Cerilliant Corporation, a reference-standards supplier, has applied for registration as an importer of controlled substances (federalregister.gov). Like the rest of these filings it is an application, not a grant, and it changes nothing on the day it posts. The reason a reference-standards importer matters to operators is indirect but real: analytical standards are what your compounding pharmacy and any testing lab rely on to verify identity and potency, so movement in that supply chain touches the quality documentation you should be demanding. This is a supply and quality-assurance signal, not a change to which substances a clinic may compound. If your pharmacy partners cite third-party potency testing, ask which standards they use and whether their supply is stable.
Source: federalregister.gov (2026-06-15)

Pull any June 30 DEA importer or bulk-manufacturer notice that names a class your suppliers handle, and note the comment-window close.

Walk your own subscribe-and-cancel flow the way the FTC would and fix any friction before it fixes you.

Get the "Riders on the Storm" drug-provisions read in front of counsel alongside Parts 1 and 3.

Eighteen days to the July 23-24 PCAC advisory meeting: confirm your compounding pharmacy's written position on the seven peptides.

Importer of Controlled Substances Application: United States Pharmacopeial Convention (2026-06-30, federalregister.gov)

FTC Secures Agreement with Havas to Restore Competition in the Digital Advertising Ecosystem (2026-06-30, ftc.gov)

FTC Sues to Stop Sprawling Enterprise Operating Unlawful Subscription Schemes (2026-06-17, ftc.gov)

Importer of Controlled Substances Application: Cerilliant Corporation (2026-06-15, federalregister.gov)

PCAC advisory meeting July 23-24, 2026 on seven peptides for the 503A bulks list (Federal Register 2026-07361, published 2026-04-16; docket FDA-2025-N-6895). Advisory recommendation only; FDA decides through rulemaking.

The Operational Side of Minnesota MSO Compliance (djholtlaw.com)

Riders on the Storm Part 2: The Drug Provisions (thefdalawblog.com)

None today.